Cited by 445Multiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersAutoimmune Neurological Disorders and Treatments

Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype

Kitley, Joanna, Woodhall, Mark, Waters, Patrick, Leite, M. Isabel, Devenney, Emma, Craig, John, Palace, Jacqueline, Vincent, Angela·2012·Neurology

Abstract

Objectives To report an association of myelin-oligodendrocyte glycoprotein (MOG) antibodies with aquaporin-4 (AQP4) antibody-seronegative neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD) in adults. Methods We describe the clinical and serologic features of 4 adult patients with an NMO/NMOSD phenotype who had antibodies to MOG. Results Twenty-seven adult AQP4-seronegative NMO/NMOSD patients were tested for MOG antibodies. Four patients (3 male, 1 female) with severe optic neuritis and/or longitudinally extensive transverse myelitis were positive. All 4 made good recoveries with steroids or plasma exchange. Two patients experienced recurrence of symptoms when corticosteroids were withdrawn quickly but none have experienced further relapses over a mean follow-up of 12 months, although 3 patients remain on treatment. Imaging abnormalities resolved fully following clinical recovery and MOG antibody titers fell in all 4 patients. MOG antibodies were not found in 44 AQP4 antibody-positive NMO/NMOSD patients, 75 adult patients with multiple sclerosis, or 47 healthy individuals. Conclusions MOG antibody-associated NMO/NMOSD could account for some cases thought previously to be AQP4-seronegative NMO/NMOSD. Our 4 patients appear to have more favorable clinical outcomes than those with typical AQP4 antibody-mediated disease. However, further studies of NMO/NMOSD and other demyelinating conditions are required to help clarify the diagnostic and prognostic rele…

Integrity signals

Registry

Crossref · 10.1212/wnl.0b013e31826aac4e

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A recently identified subgroup of AQP4-IgG seronegative NMOSD patients have antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) and may have a more favourable course.

    “A recently identified subgroup of AQP4-IgG seronegative NMOSD patients have antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) 56 and may have a more favourable course.50,57”

    From Diagnosis of multiple sclerosis: progress and challenges (2017) · cites this paper as [56]

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 16 · Cited by 445

Authors
Kitley, J., Woodhall, M., Waters, P., Leite, M. I., Devenney, E., Craig, J., Palace, J., & Vincent, A.
Affiliations
John Radcliffe Hospital (GB)
Venue
Neurology
Published
2012-09-18
Volume
79
Issue
12
Pages
1273-1277
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2052652578
Cited by
445
References
16
Citations by year
2026: 9 · 2025: 10 · 2024: 17 · 2023: 13 · 2022: 32 · 2021: 41 · 2020: 61 · 2019: 32 · 2018: 36 · 2017: 41 · 2016: 36 · 2015: 45 · 2014: 42 · 2013: 24 · 2012: 6
FWCI
26.99
Type
journal article
Language
en
Open access
closed
Locations
  • Neurology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
  • Health Sciences › Medicine › Neurology › Peripheral Neuropathies and Disorders
  • Health Sciences › Medicine › Neurology › Autoimmune Neurological Disorders and Treatments
Keywords
myelin oligodendrocyte glycoprotein antibodies, neuromyelitis optica spectrum disorder, optic neuritis, longitudinally extensive transverse myelitis, demyelinating disease, corticosteroid therapy, plasma exchange, antibody titers, clinical outcomes
MeSH terms
Adolescent, Adult, Autoantibodies, Female, Humans, Male, Neuromyelitis Optica, Aquaporin 4, Myelin-Oligodendrocyte Glycoprotein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review